This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Globalization and Health Open Access 20 April 2011
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Booth, B.L. Nat. Biotechnol. 27, 705–709 (2009).
Booth, B. Nat. Biotechnol. 25, 853–857 (2007).
Klausner A. Nat. Biotechnol. 27, 125–127 (2009).
Christenson, C. et al. The Innovator's Prescription: A Disruptive Solution for Health Care (McGraw-Hill, New York, 2009).
We would like to acknowledge the valuable comments of Z. Lynch, B. Booth, K. Perampaladas and H. Masum in shaping the overall study design and G. Williams for study data. This study was supported by New Enterprise Associates. J.C. is funded by a grant from the Bill and Melinda Gates Foundation through the Grand Challenges in Global Health initiative. We also graciously thank all the venture capital firms for participating in our qualitative and quantitative analysis.
New Enterprise Associates and Scale Venture Partners are investment firms that invest in biotech companies and biotech and A.B. and J.L.C. have a pecuniary interest in the success of their respective funds. Innovative Neurotechnologies is a virtual biotech startup and S.M. has a pecuniary interest in the success of that company.
About this article
Cite this article
Chakma, J., Calcagno, J., Behbahani, A. et al. Is it virtuous to be virtual? The VC viewpoint. Nat Biotechnol 27, 886–888 (2009). https://doi.org/10.1038/nbt1009-886
This article is cited by
Globalization and Health (2011)
Nature Biotechnology (2010)